CYTOSHRINK: Evaluating SBRT to the Primary Tumor in De Novo Advanced RCC - Aly-Khan Lalani
Aly-Khan Lalani
Aly-Khan Lalani presents CYTOSHRINK, randomizing 67 de novo advanced renal cell carcinoma patients two-to-one to stereotactic body radiation plus nivolumab/ipilimumab versus nivolumab/ipilimumab alone.
K-COMPASS Study Investigates ctDNA and KIM-1 in Oligometastatic Kidney Cancer - Chad Tang
Chad Tang
Chad Tang presents K-COMPASS, a prognostic model for oligometastatic clear cell renal cell carcinoma patients receiving radiation without systemic therapy.
